<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2125">
  <stage>Registered</stage>
  <submitdate>30/09/2008</submitdate>
  <approvaldate>30/09/2008</approvaldate>
  <nctid>NCT00763841</nctid>
  <trial_identification>
    <studytitle>Transcranial Magnetic Stimulation (TMS) for Treatment of Auditory Hallucinations</studytitle>
    <scientifictitle>A Pilot Study Using Transcranial Magnetic Stimulation (TMS) to Investigate the Role of the Temporal Cortex in Schizophrenic Patients With Auditory Hallucinations</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>07019</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Auditory Hallucinations</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Transcranial magnetic stimulation
Treatment: devices - Sham

Experimental: 1 - Stimulation will be given daily at a particular site for three days a week

Sham Comparator: 2 - 


Treatment: devices: Transcranial magnetic stimulation
Stimulation will be given daily at a particular site for three days a week

Treatment: devices: Sham


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Daily Voices Ratings (Mental Health Research Institute, Victoria)</outcome>
      <timepoint>Daily</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Over 18, with DSM-IV diagnosis of Schizophrenia and auditory hallucinations of clear
             external origins, refractory to pharmacotherapy and occurring at least 5 times per
             day.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Subjects with contraindications to TMS (e.g. epilepsy, pacemaker) or those with an
             unacceptably high risk (e.g. suicide risk) will be excluded from the study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/1999</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>18</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>School of Psychiatry - Sydney</hospital>
    <postcode>2031 - Sydney</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>The University of New South Wales</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>NSW Schizophrenia Fellowship</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Rebecca Cooper Medical Research Foundation</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Transcranial magnetic stimulation (TMS) involves the use of magnetic fields to non-invasively
      stimulate the brain. Studies overseas have suggested this may be an effective and safe
      treatment for auditory hallucinations in patients with schizophrenia. This is a
      sham-controlled, double-blind trial of TMS stimulation for the treatment of auditory
      hallucinations in patients with schizophrenia.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00763841</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Colleen Loo, MBBS, FRANZCP. MD</name>
      <address>University of NSW</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>